Seventy-six patients, spread across 14 countries, share a genetic secret that researchers are only now beginning to understand. For years, their families searched for answers to a puzzling mix of symptoms — children who spoke late, saw the world through blurry eyes, and faced developmental hurdles that doctors struggled to name. Now, in the largest study ever of a rare condition called TRND, scientists at the University of Pennsylvania's Perelman School of Medicine have finally drawn a clear map of what this disorder looks like.
TRND stands for TCF7L2-related neurodevelopmental disorder, a mouthful that hides a simple truth: a single gene, TCF7L2, plays a starring role in how the brain develops. "Neurodevelopmental" simply means it affects how the brain grows and works. When small changes, called variants, happen in this gene, they can ripple through a child's life in surprising ways.
To understand those ways, researchers teamed up with doctors in 14 countries and several U.S. cities, including Philadelphia and Boston, gathering details from 76 patients. The picture that emerged is remarkably consistent. The most common signs were speech delays, autism, developmental delays, and vision problems like nearsightedness. Many children also wrestled with orthopedic issues affecting their muscles and skeleton, and most shared distinctive facial features that had gone largely unnoticed until now.
That last detail matters deeply. Facial features act like a fingerprint that can help a doctor recognize the condition at a glance — and speed up the path to a diagnosis that might otherwise take years. The team, led by senior author Dr. David Fajgenbaum and including first author Dr. Sally Nijim, published their findings in the journal Genetics in Medicine.
The study's reach goes beyond just a checklist of symptoms. It revealed that the condition's effects can vary widely from person to person, and it flagged a possible link between certain TCF7L2 variants and type 2 diabetes in adults — a thread that researchers say deserves a closer look. Out of this work was born the TRND Network, a community connecting patients, families, physicians, and researchers, complete with a registry where newly identified families can enroll for long-term study.
For a disorder this rare, every patient's story adds a piece to the puzzle. With more families joining the registry and more research underway, the hope is that clearer recognition today will lead to better care and, one day, potential treatments tomorrow.